Rondaxe is engaged in pharmaceutical consulting and development, focusing on drug development and regulatory compliance in the pharmaceutical industry.

Rondaxe

The Henrici Group is a consultancy that provides strategic and practical guidance and support to organizations regulated by healthcare regulatory agencies, focusing on quality and compliance solutions for biopharmaceuticals.

Henrici Group

Rondaxe Pharma | 1,690 followers on LinkedIn. A trusted solution provider for all aspects of Drug Development. | Rondaxe is a drug development services company that strives to take innovative ideas from value creation to value realization. Recognizing the challenges and complexities of drug development in the disciplines covered by “Chemistry, Manufacturing and Controls”, we offer critical expertise, service and software solutions to our customers.

Our goal is to effectively help emerging pharmaceutical and biotechnology companies navigate through all phases of the drug development and commercialization process.

Process development at the interface of chemistry and biology.

David Dodds

Vice President of Business Development at Rondaxe Pharma

Dave Perritt

President, Davis Pharmaceutical Consulting and Senior Consultant at Rondaxe Pharma

Robert Davis

Shelly James

Rondaxe Pharma

https://zurl.co/2Ai0 Pfizer is making a big, half-decade commitment in China.

https://zurl.co/OLwm Yet another Big Pharma is leaving BIO.

https://zurl.co/lSZh Leqembi is still struggling for acceptance.

https://zurl.co/8Su6 Tezspire about doubled in sales volume last year, and with a new indication, it's on track to hit blockbuster status in another year or two.

https://zurl.co/vv3H These state's lack of transparency and inappropriate use of opioid money is a shame - and the other 38 states are even worse.

https://zurl.co/GiW9 NextCure just made a bold move going all in on a single preclinical program.

https://zurl.co/vwJK "The Medicare physician payment final rule continues our work to strengthen primary care ..." Wow. Really?

https://zurl.co/TpT7 J&J has good cause to celebrate; this drug has shown a decent ability to stave off multiple myeloma.

https://zurl.co/Znl6 The FDA is banning phenylephrine in many products due to lack of oral efficacy - this is going to shake things up.

Metric
Company Name	Rondaxe	Henrici Group
Symbol
MSH ID	COM:RONDAXE	COM:THEHENRICIGROUP
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Biopharmaceutical Consulting
Country	US	US
Stage
Employee Count
Website	rondaxe.com	thehenricigroup.com
LinkedIn	rondaxe-pharma	thehenricigroup
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	131
Web Traffic Growth	-0.79
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ROND

COM:RONDAXE

Rondaxe

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue